Literature DB >> 19378524

Mechanisms of analgesia of intravenous lidocaine.

Gabriela Rocha Lauretti1.   

Abstract

BACKGROUND AND OBJECTIVES: Intravenous lidocaine has been used for several indications since the decade of 1960. Its multimodal mechanism of action was the objective of this review. CONTENTS: Mechanisms of action that diverge from the classical Na+ channel blockade, the differential action of intravenous lidocaine in central sensitization, and the analgesic and cytoprotective actions, as well as the different doses of intravenous lidocaine were reviewed.
CONCLUSIONS: The final analgesic action of intravenous lidocaine is a reflection of its multifactorial action. It has been suggested that its central sensitization is secondary to a peripheral anti-hyperalgic action on somatic pain and central on neuropathic pain, which result on the blockade of central hyperexcitability. The intravenous dose should not exceed the toxic plasma concentration of 5 microg mL(-1); doses smaller than 5 mg kg(-1), administered slowly (30 minutes), under monitoring, are considered safe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19378524     DOI: 10.1590/s0034-70942008000300011

Source DB:  PubMed          Journal:  Rev Bras Anestesiol        ISSN: 0034-7094            Impact factor:   0.964


  28 in total

1.  A role for intravenous lidocaine in severe cancer-related neuropathic pain at the end-of-life.

Authors:  D Deans Buchanan; Frances J MacIvor
Journal:  Support Care Cancer       Date:  2010-04-29       Impact factor: 3.603

2.  Lidocaine infusion adjunct to total intravenous anesthesia reduces the total dose of propofol during intraoperative neurophysiological monitoring.

Authors:  Tod B Sloan; Paul Mongan; Clark Lyda; Antoun Koht
Journal:  J Clin Monit Comput       Date:  2013-08-31       Impact factor: 2.502

3.  Intravenous lidocaine and magnesium for management of intractable trigeminal neuralgia: a case series of nine patients.

Authors:  Young-Chang P Arai; Noboru Hatakeyama; Makoto Nishihara; Masahiko Ikeuchi; Makoto Kurisuno; Tatsunori Ikemoto
Journal:  J Anesth       Date:  2013-05-28       Impact factor: 2.078

Review 4.  Perioperative Use of Intravenous Lidocaine.

Authors:  Marc Beaussier; Alain Delbos; Axel Maurice-Szamburski; Claude Ecoffey; Luc Mercadal
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 5.  The efficacy and safety of intravenous lidocaine for analgesia in the older adult: a literature review.

Authors:  Harriet Daykin
Journal:  Br J Pain       Date:  2016-10-24

Review 6.  A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain.

Authors:  Ajit Rai; Howard Meng; Aliza Weinrib; Marina Englesakis; Dinesh Kumbhare; Liza Grosman-Rimon; Joel Katz; Hance Clarke
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

7.  The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It.

Authors:  Christian Bohringer; Carlos Astorga; Hong Liu
Journal:  Transl Perioper Pain Med       Date:  2020

Review 8.  Pharmacological treatment of chronic non-cancer pain in pediatric patients.

Authors:  Eapen Mathew; Eugene Kim; Kenneth R Goldschneider
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

Review 9.  Intravenous Lidocaine Infusion for the Management of Early Postoperative Pain: A Comprehensive Review of Controlled Trials.

Authors:  Robert Chu; Nelly Umukoro; Tiashi Greer; Jacob Roberts; Peju Adekoya; Charles A Odonkor; Jonathan M Hagedorn; Dare Olatoye; Ivan Urits; Mariam Salisu Orhurhu; Peter Umukoro; Omar Viswanath; Jamal Hasoon; Alan D Kaye; Vwaire Orhurhu
Journal:  Psychopharmacol Bull       Date:  2020-10-15

Review 10.  Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain.

Authors:  Janell Tully; Jai Won Jung; Anjana Patel; Alyson Tukan; Sameer Kandula; Allen Doan; Farnad Imani; Giustino Varrassi; Elyse M Cornett; Alan David Kaye; Omar Viswanath; Ivan Urits
Journal:  Anesth Pain Med       Date:  2021-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.